Interestingly, in our patient cohort we observed a significantly higher expression of FOXM1 in patients who developed a tumor recurrence or responded poorly to chemotherapy when compared with patients with a good clinical outcome (supplementary Fig. 1C). The gene discussed is FOXM1; the disease is neoplasm.